Global Cisplatin Market Size To Worth USD 27.21 Billion By 2033 | CAGR of 8.24%

Global Cisplatin Market Size To Worth USD 27.21 Billion By 2033

According to a research report published by Spherical Insights & Consulting, the Global Cisplatin Market Size is expected to grow from USD 12.33 billion in 2023 to USD 27.21 billion by 2033, at a CAGR of 8.24% during the forecast period 2023-2033. 

Browse key industry insights spread across 240 pages with 114 Market data tables and figures & charts from the report on the "Global Cisplatin Market Size, Share, and COVID-19 Impact Analysis, By Dosage form (Injections and Others), By Indications (Osteosarcoma Cancer, Breast Cancer, and Testicular Cancer), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies) and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/cisplatin-market

The cisplatin market focuses on developing, producing, and commercializing cisplatin drugs for various cancer treatments, including testicular, ovarian, bladder, and lung cancer. Cisplatin is a platinum-based chemotherapeutic medication used to treat germ cell tumors, sarcomas, carcinomas, and lymphomas. It is commonly used off-label for advanced ovarian cancer, testicular cancer, and bladder carcinoma. The FDA-approved drug cisplatin generates cytotoxicity, causing strand breakage and intra- and inter-strand crosslinks. It is used for primary peritoneal cancer and carcinomatosis and can be given intraperitoneally, intravenously, or intra-arterially. The market growth is driven by government initiatives like the Ayushman Bharat Health and Wellness Centers (AB-HWCs) and the Pradhan Mantri Jan Arogya Yojana, which provide health insurance coverage for secondary or tertiary care hospitalization to over 10.74 crore beneficiaries. The increasing prevalence of testicular cancer, which affects 5.9 new cases per 100,000 men annually, accelerates the demand for cisplatin medications. The market is expected to exceed USD 27.21 billion by 2033, driven by the positive features of cisplatin. However, the side effects associated with the use of the drugs limit the market growth.

The injections segment held the largest share of 72.11% in 2023 and is predicted to grow at a significant CAGR during the predicted period.

Based on the dosage form, the global cisplatin market is categorized as injections and others. Among these, the injections segment held the largest share of 72.11% in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is driven by improved bioavailability, patient compliance, rapid action onset, targeted drug delivery, high effectiveness, price dosing, safety, and adaptability.

The testicular cancer segment accounted for the highest market share of 34.82% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global cisplatin market is categorized as osteosarcoma cancer, breast cancer, and testicular cancer. Among these, the testicular cancer segment accounted for the highest market share of 34.82% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of the segment is attributed to the increasing prevalence of cancer, particularly testicular cancer, and the efficacy of cisplatin in managing this disease, as well as its ability to interfere with cancer cell DNA and synergize with etoposide.

The hospital pharmacies segment accounted for the greatest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global cisplatin market is categorized as online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the hospital pharmacies segment accounted for the greatest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. Hospital pharmacies collaborate, expand services, stock anti-cancer medication, offer cost-effective options, compound and dispense facilities, and provide counseling to reduce medication errors, contributing to segment growth.

North America is expected to hold the greatest share of the global cisplatin market over the forecast period.

North America is expected to hold the greatest share of the global cisplatin market over the forecast period. The demand for cisplatin in cancer treatment is driven by rising cancer cases, increased research investments, and the adoption of generic formulations. Combination therapies and collaborations among pharmaceutical companies have improved outcomes. The US market focuses on combination therapies and precision medicine to enhance treatment outcomes.

Asia Pacific is predicted to hold the fastest-growing region of the global cisplatin market throughout the estimated period. The fastest-growing market for cisplatin is driven by factors like an aging population, a growing middle class, cancer awareness, improved healthcare access, and investments in infrastructure. This growth is fueled by increased cancer incidence, better healthcare access, and regional collaborations among pharmaceutical companies.

Major key players in the global cisplatin market are Cipla, Metta Lifesciences, Fortune Healthcare Products Pvt. Ltd., Hospira, Gland Pharma, Jiangsu Haosen Pharmaceutical, Athenex Pharmaceutical, David Bull Laboratories, Pfizer, Eli Lilly and Company, Bedford Pharmaceuticals, Yunnan Biological Valley Pharmaceutical, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In January 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. received Chinese National Medical Products Administration (NMPA) marketing authorization for the programmed cell death ligand 1 (PD-L1)-directed humanized monoclonal antibody Tagitanlimab, which is used in combination with cisplatin and gemcitabine for first-line treatment of recurrent or metastatic nasopharyngeal cancer.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global cisplatin market based on the below-mentioned segments:

Global Cisplatin Market, By Dosage Form

• Injections
• Others

Global Cisplatin Market, By Indications

• Osteosarcoma Cancer
• Breast Cancer
• Testicular Cancer

Global Cisplatin Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Global Cisplatin Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter